-$0.48 expected earnings per share for Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) this quarter
Equity research analysts expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) to report earnings of ($0.48) per share for the current quarter, according to Zacks. Five analysts released earnings estimates for Syros Pharmaceuticals, with the lowest EPS estimate of $0.51 and the highest estimate of $0.45. Syros Pharmaceuticals reported earnings per share of ($0.23) in the same quarter last year, suggesting a negative 108.7% year-over-year growth rate. The company is due to release its next earnings report on Monday, January 1.
According to Zacks, analysts expect Syros Pharmaceuticals to report full year earnings of ($1.83) per share for the current year, with EPS estimates ranging from ($2.13) to ($1. $.68). For the next fiscal year, analysts expect the company to report earnings of ($1.99) per share, with EPS estimates ranging from ($2.55) to ($1.67). Zacks’ earnings per share calculations are an average average based on a survey of sell-side analysts who follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) last released its quarterly earnings data on Tuesday, March 15. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of ($0.44) by $0.02. The company posted revenue of $7.80 million for the quarter, versus a consensus estimate of $5.65 million. Syros Pharmaceuticals had a negative return on equity of 75.67% and a negative net margin of 368.52%. In the same quarter of the previous year, the company posted EPS of ($0.61).
SYRS has been the subject of a number of research reports. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a Friday, Jan. 7 report. StockNews.com downgraded Syros Pharmaceuticals from a “Hold” rating to a “Sell” rating in a Friday, April 22 research report. Finally, Piper Sandler reduced her price target on Syros Pharmaceuticals from $18.00 to $10.00 in a Monday, January 10 research report. Two analysts have rated the stock with a sell rating and three have issued a buy rating for the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $14.60.
Syros Pharmaceuticals stock opened at $0.88 on Friday. Syros Pharmaceuticals has a 52-week low of $0.78 and a 52-week high of $7.03. The company has a quick ratio of 4.33, a current ratio of 4.33 and a leverage ratio of 0.47. The company’s fifty-day moving average is $1.11 and its 200-day moving average is $2.58. The company has a market capitalization of $54.80 million, a price-earnings ratio of -0.64 and a beta of 2.09.
Several large investors have recently changed their positions in the company. Citigroup Inc. increased its stake in shares of Syros Pharmaceuticals by 49.5% during the third quarter. Citigroup Inc. now owns 9,702 shares of the company valued at $43,000 after buying 3,213 additional shares in the last quarter. Invesco Ltd. increased its holdings in Syros Pharmaceuticals by 19.9% in the third quarter. Invesco Ltd. now owns 21,843 shares of the company valued at $97,000 after acquiring an additional 3,629 shares during the period. Point72 Hong Kong Ltd increased its stake in Syros Pharmaceuticals by 168.8% in the third quarter. Point72 Hong Kong Ltd now owns 7,062 shares of the company worth $32,000 after purchasing an additional 4,435 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Syros Pharmaceuticals by 397.9% during the third quarter. BNP Paribas Arbitrage SA now owns 10,699 shares in the company worth $48,000 after purchasing an additional 8,550 shares in the last quarter. Finally, LPL Financial LLC increased its stake in shares of Syros Pharmaceuticals by 23.7% during the third quarter. LPL Financial LLC now owns 47,115 shares of the company valued at $211,000 after purchasing an additional 9,025 shares during the period. Institutional investors and hedge funds hold 81.27% of the company’s shares.
About Syros Pharmaceuticals (Get an assessment)
Syros Pharmaceuticals, Inc, a biopharmaceutical company, is focused on developing treatments for cancer and single gene diseases, and building a pipeline of genetic control drugs. The Company’s lead product candidates are tamibarotene, a selective retinoic acid receptor alpha agonist, which is in a Phase III clinical trial for a genomically defined subset of patients with myelodysplastic syndrome and a phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a new oral form of arsenic trioxide for the treatment of patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with certain advanced solid tumors.
Get a Free Copy of Zacks’ Research Report on Syros Pharmaceuticals (SYRS)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Syros Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Syros Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.